Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881435 | 0.82 | ATM (0.49) | KDRATMGAAMAPTPDE3B | |
| SCHEMBL1879161 | 0.77 | KDR (0.44) | KDRATMERN1GAAMAPT | |
| SCHEMBL1878979 | 0.76 | MEN1 (0.43) | KDRATMGAAMAPTTP53 | |
| SCHEMBL1885110 | 0.76 | GPBAR1 (0.42) | KDRATMGAAMAPTTP53 | |
| SCHEMBL457853 | 0.76 | CYP2A6 (0.47) | ATMERN1PDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL4181249 | 0.76 | ATM (0.56) | KDRATMMAPTPDE3BPDE3A | |
| SCHEMBL4182705 | 0.75 | ATM (0.55) | KDRATMGAAMAPTPDE3B | |
| SCHEMBL4180752 | 0.73 | PIK3CD (0.53) | KDRATMGAAMAPTSMN1; SMN2 | |
| SCHEMBL1597913 | 0.72 | ATM (0.51) | ATMERN1GAAMAPTTP53 | |
| SCHEMBL458716 | 0.71 | KDR (0.54) | KDRGAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | KDR 787/4885ATM 545/4885ERN1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.